Japan’s SoftBank Group has launched a joint venture, “SB TEMPUS Corp.”, with AI-enabled precision medicine company Tempus to provide precision medicine services and advance healthcare AI in Japan.
SB TEMPUS aims to offer genetic testing, medical data collection and analysis, and AI-driven treatment proposals, leveraging the expertise and technology Tempus has developed through its operations in the United States without access to patient-identified data from the United States.
The joint venture also plans to enhance diagnosis and treatment capabilities by collaborating with cancer genomic medicine hospitals, Japanese hospitals and medical facilities, pharmaceutical companies, biotech ventures, medical device companies, cancer insurance providers, and testing companies.
Matt is an award-winning storyteller, writer, and communicator currently based in Riyadh.
A native Englishman, his career has led him to diverse locations including China, Hong Kong, Iraq, Malaysia, Saudi Arabia, and the UAE.
In addition to founding HealthTechAsia, Matt is a co-founder of the non-profit Pul Alliance for Digital Health and Equity.
In a former life, he oversaw editorial coverage for Arab Health, Asia Health, Africa Health, and other key events.
In 2021, he won a Medical Travel Media Award, organised by Malaysia Healthcare Travel Council, and a Guardian Student Media Award in 2000.
Matt is an award-winning storyteller, writer, and communicator currently based in Riyadh.
A native Englishman, his career has led him to diverse locations including China, Hong Kong, Iraq, Malaysia, Saudi Arabia, and the UAE.
In addition to founding HealthTechAsia, Matt is a co-founder of the non-profit Pul Alliance for Digital Health and Equity.
In a former life, he oversaw editorial coverage for Arab Health, Asia Health, Africa Health, and other key events.
In 2021, he won a Medical Travel Media Award, organised by Malaysia Healthcare Travel Council, and a Guardian Student Media Award in 2000.
By Matthew Brady 
